Neuroscience and Behavioral Physiology

, Volume 43, Issue 1, pp 93–99 | Cite as

New Aspects of the Neurobiology of Migraine: The Role of the Hypothalamo-Pineal System

  • G. R. Tabeeva
  • A. V. Sergeev
  • S. A. Gromova


neurobiology migraine hypothalamus epiphysis melatonin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. M. Vein, Lectures in the Neurology of the Nonspecific Systems of the Brain [in Russian], Moscow (1974).Google Scholar
  2. 2.
    G. N. Kryzhanovskii (ed.), Dysregulatory Pathology [in Russian], Meditsina, Moscow (2002).Google Scholar
  3. 3.
    F. I. Komarov, S. I. Rapoport, N. K. Malinovskaya, and V. N. Anisimov, Melatonin in Health and Disease [in Russian], Moscow (2004).Google Scholar
  4. 4.
    Ya. I. Levin, Sleep and Pain [in Russian], Meditsina dlya Vsekh, No. 4, 27–28 (1998).Google Scholar
  5. 5.
    Ya. I. Levin, G. R. Tabeeva, and I. G. Khanunov, “Effects of melatonin on the structure of sleep and clinical signs in patients with fibromyalgia,” in: Current Questions in Somnology [in Russian], Moscow (1998).Google Scholar
  6. 6.
    V. V. Osipova and Ya. I. Levin, “Migraine in the ‘sleep-waking’ cycle,” Zh. Nevrol. Psikhiat., 106, No. 5, 9–15 (2006).Google Scholar
  7. 7.
    A. V. Sergeev, G. R. Tabeeva, and Yu. E. Azimova, “Central neuronal hyperexcitability – predisposition to migraine,” Ros. Zh. Boli, 27, No. 2, 3–12 (2010).Google Scholar
  8. 8.
    G. R. Tabeeva, “The chronobiology of migraine,” Zh. Nevrol. Psikhiat., 110, No. 4, Part 1, 104–112 (2010).Google Scholar
  9. 9.
    G. R. Tabeeva, and N. N. Yakhno, Migraine [in Russian], GEOTARMedia, Moscow (2011), pp. 327–408.Google Scholar
  10. 10.
    K. B. Alstadhaug, R. Salvesen, and S. Bekklund, “24-hour distribution of migraine,” Headache, 48, 95–100 (2008).PubMedCrossRefGoogle Scholar
  11. 11.
    K. B. Alstadhaug, and R. Salvesen, “Migraine – mechanisms and consequences for treatment,” Tidsskr. Nor. Laegeforen, 127, 3064–3068 (2007).PubMedGoogle Scholar
  12. 12.
    K. B. Alstadhaug, “Periodicity of migraine,” in: Migraine Disorders Research Trends, L. B. Clarke (ed.), Nova Science, New York (2007), pp. 107–144.Google Scholar
  13. 13.
    Handbook of Clinical Neurology,M. J. Amionff, F. Boller, D. F. Swaab (eds.),Vol. 79, The Human Hypothalamus: Basic and Clinical Aspects, Part I, Elsevier, Amsterdam, London (2003).Google Scholar
  14. 14.
    M. J. Amionff, F. Boller, and D. F. Swaab, “Pain and addiction,” in: Handbook of Clinical Neurology,M. J. Amionff, F. Boller, D. F. Swaab (eds.),Vol. 80, The Human Hypothalamus: Basic and Clinical Aspects, Part II, Elsevier, Amsterdam, London (2004).Google Scholar
  15. 15.
    Y. Avnon, M. Nitzan, E. Sprecher, et al., “Different patterns of parasympathetic activation in uni- and bilateral migraineurs,” Brain, 126, 1660–1670 (2003).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Bahra, S. Matharu, C. Buchel, et al., “Brainstem activation specific to migraine headache,” Lancet, 357, 1016–1017 (2001).PubMedCrossRefGoogle Scholar
  17. 17.
    T. Bartsch, M. L. Levy, P. J. Knight, and P. J. Goadsby, “Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus,” Pain, 117, 30–39 (2005).PubMedCrossRefGoogle Scholar
  18. 18.
    L. Benjamin, M. J. Levy, M. P. Lasalandra, et al., “Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study,” Neurobiol. Dis., 16, 500–505 (2004).PubMedCrossRefGoogle Scholar
  19. 19.
    I. Bettahi, D. Pozo, C. Osuma, et al., “Melatonin reduces nitric oxide synthase activity in rat hypothalamus,” J. Pineal Res., 20, 205–210 (1996).PubMedCrossRefGoogle Scholar
  20. 20.
    M. E. Bigal, R. B. Lipton, P. R. Holland, and P. J. Goadsby, “Obesity, migraine, and chronic migraine – possible mechanisms of interaction,” Neurology, 68, 1851–1861 (2007).PubMedCrossRefGoogle Scholar
  21. 21.
    H. Bolay, U. Reuter, A. K. Dunn, et al., “Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model,” Nat. Med., 8, 136–142 (2002).PubMedCrossRefGoogle Scholar
  22. 22.
    J. Brun, B. Claustrat, P. Saddier, and G. Chazot, “Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses,” Cephalgia, 15, 136–139 (1995).CrossRefGoogle Scholar
  23. 23.
    R. Burstein and M. Jakubowski, “A unitary hypothesis for multiple triggers of the pain and strain of migraine,” J. Comp. Neurol., 493, 9–14 (2005).PubMedCrossRefGoogle Scholar
  24. 24.
    E. Carstens, “Hypothalamic inhibition of rat dorsal horn neuronal responses to noxious skin heating,” Pain, 25, 95–107 (1986).PubMedCrossRefGoogle Scholar
  25. 25.
    O. Casez, Y. Dananchet, and G. Besson, “Migraine and somnambulism,” Neurology, 65, 1334–1336 (2005).PubMedCrossRefGoogle Scholar
  26. 26.
    J. I. Chuang, N. Mohan, M. L. Reitz, and R. J. Reiter, “Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen,” Cell Biol. Int., 20, 687–692 (1996).PubMedCrossRefGoogle Scholar
  27. 27.
    B. Claustrat, J. Brun, M. Geoffriau, et al., “Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus,” Cephalgia, 17, 511–517 (1997).CrossRefGoogle Scholar
  28. 28.
    B. Claustrat, C. Loisy, J. Brun, et al., “Nocturnal plasma melatonin levels in migraine: a preliminary report,” Headache, 29, 242–245 (1989).PubMedCrossRefGoogle Scholar
  29. 29.
    N. Dahmen, M. Kasten, S. Wieczorek, et al., “Increased frequency of migraine in narcoleptic patients: a confirmatory study,” Cephalgia, 23, 14–19 (2003).CrossRefGoogle Scholar
  30. 30.
    M. W. De Vries and F. P. Peeters, “Melatonin as a therapeutic agent in the treatment of sleep disturbances in depression,” J. Nerv. Ment. Dis., 185, 201–202 (1997).CrossRefGoogle Scholar
  31. 31.
    G. Della Marca, C. Vollono, M. Rubino, et al., “Dysfunction of arousal systems in sleep-related migraine without aura,” Cephalgia, 26, 857–864 (2006).CrossRefGoogle Scholar
  32. 32.
    M. Denuelle, N. Fabre, P. Payoux, et al., “Hypothalamic activation in spontaneous migraine attacks,” Headache, 47, 1418–1426 (2007).PubMedGoogle Scholar
  33. 33.
    J. D. Dexter, “The relationship between stage III + IV + REM sleep and arousals with migraine,” Headache, 19, 364–369 (1979).PubMedCrossRefGoogle Scholar
  34. 34.
    R. Dubbels, R. J. Reiter, E. Klenke, et al., “Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry,” J. Pineal Res., 18, 28–31 (1995).PubMedCrossRefGoogle Scholar
  35. 35.
    M. Ebadi, P. Govitrapong, P. Phansuwan-Pujito, et al., “Pineal opioid receptors and analgesic action of melatonin,” J. Pineal Res., 24, 193–200 (1998).PubMedCrossRefGoogle Scholar
  36. 36.
    M. T. Epstein, J. M. Hockaday, and T. D. Hockaday, “Migraine and reproductive hormones throughout the menstrual cycle,” Lancet, No. 1, 543–548 (1975).Google Scholar
  37. 37.
    A. Espinar, A. Garcia-Oliva, E. M. Isorn, et al., “Neuroprotection by melatonin from glutamate-induced excitotoxicity during development of the cerebellum in the chick embryo,” J. Pineal Res., 28, 81–88 (2000).PubMedCrossRefGoogle Scholar
  38. 38.
    F. Facchinetti, L. Sgarbi, and F. Piccinini, “Hypothalamic resetting at puberty and the sexual dimorphism of migraine,” Funct. Neurol., 15, Supplement 3, 137–142 (2000).PubMedGoogle Scholar
  39. 39.
    J. C. Galego, J. P. Cupillo, J. A. Cordeiro, and W. A. Tognola, “Clinical features of episodic migraine and transformed migraine: a comparative study,” Arq. Neuropsiquiatr., 60, 912–916 (2002).PubMedCrossRefGoogle Scholar
  40. 40.
    J. J. Garcia, R. J. Reiter, J. M. Guerrero, et al., “Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation,” FEBS Lett., 408, 297–300 (1997).PubMedCrossRefGoogle Scholar
  41. 41.
    N. J. Giffin, L. Ruggiero, R. B. Lipton, et al., “Premonitory symptoms in migraine. An electronic diary study,” Neurology, 60, 935–940 (2003).PubMedCrossRefGoogle Scholar
  42. 42.
    R. Goder, G. Fritzer, A. Kapsokalyvas, et al., “Polysomnographic findings in nights preceding a migraine attack,” Cephalgia, 21, 31–37 (2001).CrossRefGoogle Scholar
  43. 43.
    C. Godson and S. M. Reppert, “The Mel1a melatonin receptor is coupled to parallel signal transduction pathways,” Endocrinology, 138, 397–404 (1997).PubMedCrossRefGoogle Scholar
  44. 44.
    S. Gori, N. Morelli, M. Maestri, et al., “Sleep quality, chronotypes and preferential timing of attacks in migraine without aura,” J. Headache Pain, 6, 258–260 (2005).PubMedCrossRefGoogle Scholar
  45. 45.
    F. Granella, G. Sances, C. Zanferrari, et al., “Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women,” Headache, 33, 385–389 (1993).PubMedCrossRefGoogle Scholar
  46. 46.
    B. Guldiken, S. Guldiken, M. Demier, et al., “Low leptin levels in migraine: a case controls study,” Headache, 48, 1103–1107 (2008).PubMedCrossRefGoogle Scholar
  47. 47.
    S. R. Haut, M. E. Bigal, and R. B. Lipton, “Chronic disorders with episodic manifestations: focus on epilepsy and migraine,” Lancet Neurol., 5, 148–157 (2006).PubMedCrossRefGoogle Scholar
  48. 48.
    S. P. Hunt, A. Pini, and G. Evan, “Introduction of c-fos-like protein in spinal cord neurons following sensory stimulation,” Nature, 328, 1686–1704 (1987).CrossRefGoogle Scholar
  49. 49.
    A. Kalsbek, I. F. Palm, S. E. La Fleur, et al., “SCN outputs and the hypothalamic balance of life,” J. Biol. Rhythms, 21, 458–469 (2006).CrossRefGoogle Scholar
  50. 50.
    S. Kutlu, M. Ozcan, S. Canpolat, et al., “Effect of ghrelin on pain threshold in mice,” Firat. Tip. Dergisi., 10, 898–91 (2005).Google Scholar
  51. 51.
    M. Lauritzen, “Pathophysiology of the migraine aura. The spreading depression theory,” Brain, 117, 199–210 (1994).PubMedCrossRefGoogle Scholar
  52. 52.
    E. M. Lichten, J. B. Lichten, A. Whitty, and D. Pieper, “The confirmation of a biochemical marker for women’s hormonal migraine: the depo-estradiol challenge test,” Headache, 35, 367–371 (1996).CrossRefGoogle Scholar
  53. 53.
    J. Lu, S. Sherman, M. Devor, and C. B. Saper, “A putative flip-flop switch for control of REM sleep,” Nature, 441, 589–594 (2006).PubMedCrossRefGoogle Scholar
  54. 54.
    I. Lund, Y. Ge, L. C. Yu, et al., “Repeated massage-like stimulation induces long-term effects on nociception – contribution of oxytocinergic mechanisms,” Eur. J. Neurosci., 16, 330–338 (2002).PubMedCrossRefGoogle Scholar
  55. 55.
    A. Malick, M. Jakubowski, J. K. Elmquist, et al., “A neurohistochemical blueprint for pain-induced loss of appetite,” Proc. Natl. Acad. Sci. USA, 98, 9930–9935 (2001).PubMedCrossRefGoogle Scholar
  56. 56.
    A. Malick, A. M. Strassman, and R. Burnstein, “Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat,” J. Neurophysiol., 84, 2078–2112 (2000).PubMedGoogle Scholar
  57. 57.
    S. P. Markey, S. Higa, M. Shih, et al., “The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion,” Clin. Chim. Acta, 150, 221–225 (1985).PubMedCrossRefGoogle Scholar
  58. 58.
    J. L. Medina and S. Diamond, “Cyclical migraine,” Arch. Neurol., 38, 343–344 (1981).PubMedCrossRefGoogle Scholar
  59. 59.
    A. Menendez-Pelaez, B. Poeggeler, R. J. Reiter, et al., “Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence,” J. Cell. Biochem., 53, 373–382 (1993).PubMedCrossRefGoogle Scholar
  60. 60.
    F. P. Monnet, “Melatonin modulates [3H]serotonin release in the rat hippocampus: effects of circadian rhythm,” J. Neuroendocrinol., 14, 194–199 (2002).PubMedCrossRefGoogle Scholar
  61. 61.
    G. Murialdo, S. Fonzi, P. Costelli, et al., “Urinary melatonin excretion throughout the ovarian cycle in menstrually regulated migraine,” Cephalgia, 14, 205–209 (1994).CrossRefGoogle Scholar
  62. 62.
    J. E. Nagtegaal, M. W. Laurant, G. A. Kerkhof, et al., “Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome,” J. Psychosom. Res., 48, 45–50 (2000).PubMedCrossRefGoogle Scholar
  63. 63.
    R. J. Orts and B. Benson, “Inhibition effects on serum and pituitary LH by a melatonin-free extract of bovine pineal glands,” Life Sci. II, 12, 513–519 (1973).PubMedCrossRefGoogle Scholar
  64. 64.
    S. Overem, J. A. van Vliet, G. J. Lammers, et al., “The hypothalamus in episodic brain disorders,” Lancet Neurol., No. 1, 437–444 (2002).Google Scholar
  65. 65.
    T. Paiva, A. Batista, P. Martins, and A. Martins, “The relationship between headaches and sleep disturbance,” Headache, 35, 590–596 (1995).PubMedCrossRefGoogle Scholar
  66. 66.
    M. F. Peres, M. Sanchez del Rio, M. L. Seabra, et al., “Hypothalamic involvement in chronic migraine,” J. Neurol. Neurosurg. Psychiatry, 71, 747–751 (2001).PubMedCrossRefGoogle Scholar
  67. 67.
    M. F. Peres, M. A. Stiles, H. C. Siow, et al., “Chronobiological features in episodic and chronic migraine,” Cephalgia, 23, 590–591 (2003).Google Scholar
  68. 68.
    M. F. Peres, E. Zukerman, F. da Cunha Tanuri, et al., “Melatonin, 3mg, is effective for migraine prevention,” Neurology, 63, 757 (2004).PubMedCrossRefGoogle Scholar
  69. 69.
    M. F. P. Peres, “Melatonin, the pineal gland and their implication for headache disorders,” Cephalgia, 25, 403–411 (2005).CrossRefGoogle Scholar
  70. 70.
    S. J. Perotuka, “Migraine: a chronic sympathetic nervous system disorder,” Headache, 44, 53–64 (2004).CrossRefGoogle Scholar
  71. 71.
    S. J. Peroutka, “Dopamine and migraine,” Neurology, 49, 650–656 (1997).PubMedCrossRefGoogle Scholar
  72. 72.
    C. J. M. Poole and S. L. Lightman, “Inhibition of vasopressin secretion during migraine,” J. Neurol. Neurosurg. Psychiatry, 51, 1441–1444 (1988).PubMedCrossRefGoogle Scholar
  73. 73.
    N. M. Ramadan, “The link between glutamate and migraine,” CNS Spectr., 8, 446–449 (2003).PubMedGoogle Scholar
  74. 74.
    R. J. Reiter, J. R. Calvo, M. Karbownik, et al., “Melatonin and its relation to the immune system and inflammation,” Ann. N.Y. Acad. Sci., 917, 376–386 (2000).PubMedCrossRefGoogle Scholar
  75. 75.
    R. J. Reiter, “Pineal melatonin: cell biology of its synthesis and of its physiological interactions,” Endocr. Rev., 12, 151–180 (1991).PubMedCrossRefGoogle Scholar
  76. 76.
    S. M. Reppert, C. Godson, C. D. Mohle, et al., “Molecular characterization of a second melatonin receptor expressed in human retina and grain: the Mel1b melatonin receptor,” Proc. Natl. Acad. Sci. USA, 92, 8734–8738 (1995).PubMedCrossRefGoogle Scholar
  77. 77.
    G. Sances, F. Granella, R. E. Nappi, et al., “Course of migraine during pregnancy and postpartum: a prospective study,” Cephalgia, 23, 197–205 (2003).CrossRefGoogle Scholar
  78. 78.
    E. Savaskan, G. Olivieri, L. Brydon, et al., “Cerebrovascular melatonin MT1-receptor alterations in patients with Alzheimer’s disease,” Neurosci. Lett., 308, 9–12 (2001).PubMedCrossRefGoogle Scholar
  79. 79.
    A. Y. Shaikh, J. Xu, Y. Wu, et al., “Melatonin protects bovine cerebral endothelial cells from hyperoxia-induced DNA damage and death,” Neurosci. Lett., 229, 193–197 197Google Scholar
  80. 80.
    S. D. Silberstein, A. H. Elkind, C. Schreiber, and C. Keywood, “A randomized trial of frovatriptan for intermittent prevention of menstrual migraine,” Neurology, 63, 261–269 (2004).PubMedCrossRefGoogle Scholar
  81. 81.
    S. D. Silberstein, “The role of sex hormones in headache,” Neurology, 42, No. 3, Suppl. 2, 37–42 (1992).Google Scholar
  82. 82.
    W. F. Stewart, A. Shechter, and B. K. Rasmussen, “Migraine prevalence: a review of population-based trends,” Neurology, 44, Suppl. 4, 17–23 (1994).Google Scholar
  83. 83.
    F. Wang, J. C. Li, C. F. Wu, et al., “Hypnotic activity of melatonin: involvement of semicarbazide hydrochloride, blocker of synthetic enzyme for GABA,” Acta Pharmacol. Scand., 23, 860–864 (2002).Google Scholar
  84. 84.
    C. Weiler, A. May,V. Limmroth, et al., “Brain stem activation in spontaneous human migraine attacks,” Nat. Med., No. 1, 658–660 (1995).Google Scholar
  85. 85.
    F. S. Wu, Y. C. Yang, and J. J. Tsai, “Melatonin potentiates the GABA(A) receptor-mediated current in cultured chick spinal cord neurons,” Neurosci. Lett., 260, 177–180 (1999).PubMedCrossRefGoogle Scholar
  86. 86.
    W. B. Young, M. F. Pres, and T. D. Rozen, “Modular headache theory,” Cephalgia, 21, 842–849 (2001).CrossRefGoogle Scholar
  87. 87.
    L. Y. Zang, G. Cosma, H. Gardner, and V. Vallyathan, “Scavenging of reactive oxygen species by melatonin,” Biochem. Biophys. Acta 1425, 469–477 (1998).PubMedCrossRefGoogle Scholar
  88. 88.
    Q. Z. Zhang, Y. S. Gong, and J. T. Zhang, “Antagonistic effects of melatonin on glutamate release and neurotoxicity in cerebral cortex,” Zhongguo Yao Li Xue Bao, 20, 829–834 (1999).PubMedGoogle Scholar
  89. 89.
    N. Zisapel, “Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting,” Cell. Mol. Neurobiol., 21, 605–616 (2001).PubMedCrossRefGoogle Scholar
  90. 90.
    N. Zurak, “Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks,” Cephalgia, 17, 723–728 (1997).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • G. R. Tabeeva
    • 1
  • A. V. Sergeev
    • 1
  • S. A. Gromova
    • 1
  1. 1.Department of Neurology and Clinical NeurophysiologyResearch Center of the First I. M. Sechenov Moscow State Medical UniversityMoscowRussia

Personalised recommendations